Protagonist Therapeutics, Inc. (PTGX)
Develops oral peptide drugs to treat psoriasis, blood disorders, and obesity.
$135.61+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+151.9%
The outlook
PTGX is trading near the top of its 52-week range and well above its major moving averages, reflecting sustained upward momentum. Analyst consensus is strongly bullish, though the average price target sits about 2% below current levels. The stock's position suggests market enthusiasm, though valuations appear stretched relative to analyst expectations.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 13 analysts
Price trendAbove its 50- & 200-day averages
52-week range92% of the way from its 52-week low to high
Price targetAvg target -2% vs current price
Analyst price target
~12-month · 13 analysts$133.31average target-1.7% vs now
Now $135.61
Low $110.00High $172.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$8.72B
52-wk high
$143.29
52-wk low
$50.49
50-day avg
$116.79
200-day avg
$96.08
Trailing P/E
—